8:45 am Chair’s Opening Remarks
9:00 am Workshop: Mitigating Toxicity & Ensuring Safety in Claudin-Targeted Cancer Therapies
Synopsis
- This workshop will focus on strategies to mitigate toxicity and enhance safety in Claudin-targeted therapies, addressing common side effects and preclinical profiling. Participants will learn about clinical trial designs and approaches to manage patient safety effectively
Delving into Claudin Biology & Translational Success in Claudin-Targeted Therapies
9:30 am Panel Discussion: Insights into Claudin Biology & its Impact On Cancer Progression
Synopsis
- Understanding the dynamic expression patterns of Claudin 18.2, 6, and 9 in different cancer stages and the implications for therapeutic targeting
- Outlining the role of claudin proteins in tumor microenvironment interactions and how these interactions influence cancer progression and metastasis
- Identifying how understanding claudin biology can inform clinical strategies and improve therapeutic outcomes, including the development of targeted delivery systems and combination therapies
10:00 am Translational Development: Bridging Preclinical Findings to Clinical Success in Claudin-Targeted Therapies
Synopsis
- Understanding the importance of developing companion diagnostics for Claudintargeted therapies, including the identification and validation of biomarkers to ensure patient selection
- Showcasing strategies to address challenges in translational development, such as achieving target specificity, managing toxicity profiles, and optimizing therapeutic windows
- Analyzing case studies highlighting the successful transition of Claudin-targeted therapies from preclinical stages to clinical trials, with a focus on lessons learned and best practices
10:30 am Showcasing Claudin18.2 T Cell Engager for GC & PDAC Malignancies
Synopsis
- Reviewing CLDN18.2 expression as a target for GC and PDAC tumours
- Strategies for increasing the therapeutic index of T cell engagers and application to CLDN18.2
- Preclinical data on AZD5863 – a clinical stage CLDN18.2 T cell engager
11:00 am Virtual Networking Session
Synopsis
Return to the Networking Zone to reconnect and break down your takeaways so far with your other attendees. Make sure to check out the questions across the different meeting areas!
11:30 am Coffee Break
Assessing Innovative Therapeutic Approaches & Toxicity Management in Claudin-Targeted Therapies
12:00 pm Next-Generation Cell Therapies Targeting Claudin: Overcoming Challenges & Improving Outcomes
Synopsis
- Showcasing the latest advancements in next-generation cell therapies targeting claudin, emphasizing novel approaches beyond CAR-T
- Understanding improvements in toxicity profiles and the durability of therapeutic responses in solid tumors
- Highlighting early clinical data and preclinical insights to illustrate the effectiveness and potential of these innovative therapies
12:30 pm Potent next-gen ISAC targeting Claudin 18.2
Synopsis
Efficacy in low-antigen-density tumors
Demonstrated superiority to ADCs in preclinical studies
Immunologic memory with epitope spreading provides promise of durable responses and prevents recurrence MTD ≥ 12 mg/kg in NHPs with differentiated toxicology profile from cytotoxic ADCs
Preparing for first-in-human clinical trial
12:45 pm Translational Development: Bridging Preclinical Findings to Clinical Success in Claudin-Targeted Therapies
Synopsis
- Understanding the importance of developing companion diagnostics for Claudintargeted therapies, including the identification and validation of biomarkers to ensure patient selection
- Showcasing strategies to address challenges in translational development, such as achieving target specificity, managing toxicity profiles, and optimizing therapeutic windows
- Analyzing case studies highlighting the successful transition of Claudin-targeted therapies from preclinical stages to clinical trials, with a focus on lessons learned and best practices